These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37486980)

  • 1. Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model.
    Monzo HJ; Kalander K; Hyytiäinen MM; Elbasani E; Wall J; Moyano-Galceran L; Tanjore Ramanathan J; Jukonen J; Laakkonen P; Ristimäki A; Carlson JW; Lehti K; Salehi S; Puolakkainen P; Haglund C; Seppänen H; Leppä S; Ojala PM
    Mol Cancer Ther; 2023 Nov; 22(11):1319-1331. PubMed ID: 37486980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Stage-Specific Embryonic Antigen 4 (SSEA-4) in Triple Negative Breast Cancer by CAR T Cells Results in Unexpected on Target/off Tumor Toxicities in Mice.
    Pfeifer R; Al Rawashdeh W; Brauner J; Martinez-Osuna M; Lock D; Herbel C; Eckardt D; Assenmacher M; Bosio A; Hardt OT; Johnston ICD
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
    Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
    Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective Targeting of TAG72
    Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
    Front Immunol; 2018; 9():2268. PubMed ID: 30510550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
    Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
    Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
    Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
    J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
    Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
    Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.
    Rodriguez-Garcia A; Sharma P; Poussin M; Boesteanu AC; Minutolo NG; Gitto SB; Omran DK; Robinson MK; Adams GP; Simpkins F; Powell DJ
    Mol Ther; 2020 Feb; 28(2):548-560. PubMed ID: 31870622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer.
    Leong L; Tan HL; Cua S; Yong KSM; Chen Q; Choo A
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells.
    Martín-Otal C; Lasarte-Cia A; Serrano D; Casares N; Conde E; Navarro F; Sánchez-Moreno I; Gorraiz M; Sarrión P; Calvo A; De Andrea CE; Echeveste J; Vilas A; Rodriguez-Madoz JR; San Miguel J; Prosper F; Hervas-Stubbs S; Lasarte JJ; Lozano T
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35918123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30
    Hong LK; Chen Y; Smith CC; Montgomery SA; Vincent BG; Dotti G; Savoldo B
    Cancer Immunol Res; 2018 Oct; 6(10):1274-1287. PubMed ID: 30087115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy.
    Zhang Y; Wang P; Wang T; Fang Y; Ding Y; Qian Q
    J Transl Med; 2021 Feb; 19(1):82. PubMed ID: 33602263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
    Li T; Wang J
    BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel TREM1/DAP12-based multiple chain CAR-T cell targets PTK7 in ovarian cancer therapy.
    Xu T; Wang C; Wang X; Wang E; Wang B; Sun M
    Med Oncol; 2023 Jul; 40(8):226. PubMed ID: 37405498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
    Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
    Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma.
    Huo Q; Lv J; Zhang J; Huang H; Hu H; Zhao Y; Zhang X; Wang Y; Zhou Y; Qiu J; Ye Y; Huang A; Chen Y; Qin L; Qin D; Li P; Cai G
    Cytotherapy; 2023 Oct; 25(10):1037-1047. PubMed ID: 37436338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.